Table 1.
Model data input values for cost effectiveness analysis, antiretroviral monitoring study, Tororo and Busia Districts, Uganda, 2003-7. All costs are in US $
| Parameter | Base case value | Source(s) | ||
|---|---|---|---|---|
| Clinical/CD4/viral load | Clinical/CD4 | Clinical | ||
| Frequency of health events: | ||||
| Deaths (per 100 person years)* | 3.7 | 4.1 | 5.8 | Trial11 |
| Severe morbid events (per 100 person year)* | 1.7 | 2.7 | 4.9 | Trial11 |
| Disability adjusted life years per clinical event during trial: | ||||
| Deaths | 2.32 | Trial,11 Global Burden of Disease18 | ||
| Severe morbid events (range) | 0.019-0.75 | Global Burden of Disease,18 expert opinion | ||
| Unit costs of monitoring tests: | ||||
| CD4 | $4.68 | $4.68 | — | Downing (Clinton Fund); trial11 |
| Viral load | $29.64 | — | — | COBAS Amplicor; trial11 |
| % Change in antiretroviral drug regimen (annual) | 0.7% | 0.4% | 1.8% | Trial11 |
| Costs of use during trial (per person year): | ||||
| Laboratory monitoring of CD4s and viral loads | $137.30 | $18.74 | $0 | Trial11 |
| Antiretroviral drugs (discounted; observed mix of first and second line regimens during trial) | $160 | $156 | $175 | Trial,11 Médecins Sans Frontières19 |
| Diagnostic tests | $168 | $168 | $164 | Trial11 |
| Opportunistic infection treatment including tuberculosis (outpatient) | $122 | $123 | $127 | Trial11 |
| Inpatient costs | $2.05 | $1.96 | $2.87 | Trial11 |
*From intention to treat analysis, adjusted for multivariate regression findings (see text).